CJC-1295 Life Events That Affect Dosing: Surgery, Travel, Illness, and More
HealthRX.com
No approved CJC-1295 dose exists to adjust for life events
Key numbers
- 30 to 250 micrograms/kgResearch doses given to healthy adults, not recommended or approved dosesSource: fda.gov, as cited Nov 7, 2026
- 70%Share of treated subjects with injection-site reactions in the first healthy-volunteer trialSource: fda.gov, as cited Nov 7, 2026
- 63%Share of treated healthy volunteers with headache, versus 14% on placeboSource: fda.gov, as cited Nov 7, 2026
At a glance
- Regulatory status / Not an FDA-approved drug; FDA found no approved product in any country it searched [1]
- Approved dose / None; study injections were about 30 to 250 micrograms/kg, not recommended doses [1][2]
- Human evidence / Three published studies, all the DAC form, in healthy volunteers [1]
- Half-life / 5.8 to 8.1 days after one subcutaneous injection [2]
- Sport / Named on WADA's Prohibited List, banned at all times [3]
Is there a CJC-1295 dose to adjust?
No. FDA found no approved product containing any form of CJC-1295 in the countries it searched [1]. There is no approved dose to raise, lower or reschedule around an operation, a trip or a fever.
The doses in the published record come from research: single subcutaneous injections of roughly 30 to 250 micrograms/kg in healthy adults, or two to three doses given weekly or every two weeks [1][2]. Those were study doses, not recommendations.
Questions worth asking
What the human studies measured
Teichman and colleagues ran two randomized, placebo-controlled, double-blind, ascending-dose trials lasting 28 and 49 days in healthy adults aged 21 to 61 [2]. After a single injection, mean plasma GH rose 2- to 10-fold for 6 days or more and IGF-I rose 1.5- to 3-fold for 9 to 11 days, with an estimated half-life of 5.8 to 8.1 days; after multiple doses, IGF-I stayed above baseline for up to 28 days [2].
Ionescu and Frohman gave healthy men aged 20 to 40 one injection of 60 or 90 micrograms/kg; a week later GH pulse frequency and size were unchanged, trough GH rose about 7.5-fold, mean GH rose 46% and IGF-I 45% [4].
Surgery, fever and other illness
FDA identified no published study of any form of CJC-1295 in people with a disease [1]. One trial in HIV-associated visceral obesity (NCT00267527) is listed on ClinicalTrials.gov and was terminated [1].
FDA's briefing says ConjuChem withdrew CJC-1295 DAC from clinical trials in 2006 after a participant in a phase 2 trial in HIV lipodystrophy (192 enrolled) died. Per anecdotal news reports FDA cites, the person had chest discomfort 2 hours after an 11th weekly dose, and an ECG showed an acute heart attack; the attending physician's most likely explanation was undiagnosed coronary artery disease with plaque rupture [1]. The data were never published, so a causal link is neither shown nor excluded [1].
In the healthy-volunteer trials, injection-site reactions occurred in about 70% of treated subjects in study 1 and in all treated subjects in study 2, and headache in 63% versus 14% on placebo, with most events more common at 125 or 250 micrograms/kg [1][2]. In Ionescu and Frohman, dose-dependent increases in heart rate were reported [1]. FDA said the human studies were short, small and mostly single-dose, so long-term safety is unknown [1].
Travel and sport
FDA noted that CJC-1295 products sold online are mostly labeled "research use only", including blends with ipamorelin and GHRPs [1].
WADA names CJC-1295 and CJC-1293 in S2.2.4 as growth hormone-releasing hormone analogues, prohibited at all times, in and out of competition [3]. CJC-1295 is also named in WADA's 2027 Prohibited List [5].
Frequently asked questions
Is there a special CJC-1295 dose for surgery or illness?
Is CJC-1295 banned in sport?
What side effects appeared in the human studies?
References
Show all 5 referencesHide references
- U.S. Food and Drug Administration.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- World Anti-Doping Agency.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7.
- World Anti-Doping Agency.